Ruxolitinib

USDailyMed:Ruxolitinib AU:C L01EJ01(WHO)D11AH09(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile 941678-49-5Y 25126798 5688 DB08877Y 25027389Y 82S8X8XX8H D09959Nas salt:D09960N ChEMBL1789941N RXT (PDBe,RCSB PDB) DTXSID10240930 Interactive image N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1 InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1YKey:HFNKQEVNSGCOJV-OAHLLOKOSA-NY Ruxolitinib(sold under the brand namesJakafiandJakaviamong others, and asOpzelurain cream form) is amedicationused for the treatment of intermediate or high-riskmyelofibrosis,a type ofmyeloproliferative neoplasmthat affects thebone marrow;polycythemia vera, when there has been an inadequate response to or intolerance ofhydroxyurea;and steroid-refractory acutegraft-versus-host disease.Ruxolitinib is aJanus kinase inhibitor.It was developed and marketed byIncyte Corpin the US under the brand name Jakafi,and byNovartiselsewhere in the world, under the brand name Jakavi. It was approved for medical use in the United States in 2011,and in the European Union in 2012.Ruxolitinib is the first FDA-approved pharmacologic treatment to address repigmentation invitiligopatients. The crystal structure of ruxolitinib and of its dihydrate form are known.